Abdominal compartment syndrome
공공데이터포털
Intra-abdominal hypertension (IAH) associated with organ dysfunction defines the abdominal compartment syndrome (ACS). Elevated intra-abdominal pressure (IAP) adversely impacts pulmonary, cardiovascular, renal, splanchnic, musculoskeletal/integumentary, and central nervous system physiology. The combination of IAH and disordered physiology results in a clinical syndrome with significant morbidity and mortality. The onset of the ACS requires prompt recognition and appropriately timed and staged intervention in order to optimize outcome. The history, pathophysiology, clinical presentation, and management of this disorder is outlined.
Dataset for Impact of living conditions on cardiovascular function in atherosclerosis-prone mice and smoke exposure
공공데이터포털
Raw data for all figures and tables in manuscript for study analyzing the impact of living conditions on cardiovascular function in ApoE -/- mice. This dataset is associated with the following publication: Fiamingo, M., S. Toler, K. Lee, W. Oshiro, Q. Krantz, P. Evansky, D. Davies, M. Gilmour, A. Farraj, and M. Hazari. Depleted housing elicits cardiopulmonary dysfunction after a single flaming eucalyptus wildfire smoke exposure in a sex-specific manner in ApoE knockout mice.. Cardiovascular Toxicology. Humana Press Incorporated, Totowa, NJ, USA, 24: 852-869, (2024).
Noninferiority trials
공공데이터포털
In one of the biggest dilemmas facing cardiovascular clinical research, clinical trials are increasingly being required to show benefits on clinical end-points rather than surrogate end-points, while at the same time the incremental benefits of newer treatments are getting smaller. These two factors have a huge impact on sample size, which has led some investigators to design trials to show that the new treatment has an effect similar to that of the standard, rather than outright superiority. Recent examples of fibrinolytic trials that have demonstrated similar effects of two drugs are ASSENT (Assessment of the Safety and Efficacy of a New Thrombolytic)-2, GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)-III, and COBALT (Continuous Infusion Versus Double-Bolus Administration of Alteplase) [1,2,3,4]. However, as discussed by several authors [5,6,7,8], there are issues with trials of this type that make them considerably less credible than superiority trials.